Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelinesEnrollment underway in ...
Pharvaris (PHVS) Projected to Post Earnings on Wednesday
Pharvaris (NASDAQ:PHVS – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on ...
Vanguard Group Inc. Has $164.62 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Vanguard Group Inc. increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 7.8% during the ...
Last Real Indians11h
Another Inmate Death at Federally Operated Detention Center in Red Lake
The recent death of an inmate at a Bureau of Indian Affairs regulated jail in northern Minnesota is one of several in the last several years. The troubled detention center on the Red Lake Indian Reser ...
Managed Healthcare Executive5h
18-Month Retrospective Claims Analysis Study Information on Ruxolitinib
Panelists discuss how the 18-month retrospective claims analysis of ruxolitinib revealed sustained efficacy in atopic dermatitis management, with significant reductions in disease flares, healthcare ...